Actively Recruiting

Phase 1
Phase 2
Age: 2Years - 18Years
All Genders
NCT05588323

Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids

Led by Shionogi · Updated on 2026-04-29

24

Participants Needed

16

Research Sites

179 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of naldemedine and nor-naldemedine after a single oral dose of naldemedine in pediatric participants who are receiving or about to receive opioids.

CONDITIONS

Official Title

Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids

Who Can Participate

Age: 2Years - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants with cancer or non-cancer pain who are receiving or about to receive acute or chronic opioid treatment.
  • Participants with newly diagnosed constipation, a history of constipation treated with laxatives, or expected to develop constipation after opioid treatment.
  • Able to stay in the clinic for blood sampling for at least 12 hours after the first dose and return for a 24-hour blood sample.
  • Body mass index within approximately the 3rd to 97th percentile for their age according to WHO Child Growth Standards.
  • Aged between 2 and 18 years.
Not Eligible

You will not qualify if you...

  • History of gastrointestinal neoplasm or ongoing GI problems or recent/planned GI surgery within the last year.
  • Signs or symptoms of gastrointestinal obstruction or recurrent obstruction increasing risk of perforation.
  • Inability to eat or swallow or need for a nasogastric tube.
  • No bowel movements for 7 consecutive days at consent or on the first study day.
  • History of more than 1 week of Grade 3 neutropenia or thrombocytopenia with clinical effects.
  • Requires mechanical ventilation.
  • Severe Grade 3 or above liver or kidney impairment, including end-stage renal disease needing hemodialysis.
  • Progressive neurological disorders or conditions affecting the blood-brain barrier.
  • Currently receiving the first cycle of chemotherapy.
  • Previous use of naldemedine.
  • Positive pregnancy test for females of childbearing potential.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 16 locations

1

University Center Mother Theresa , Hospital - Onco-hematology department

Tirana, Albania

Not Yet Recruiting

2

Yeolyan Hematology. , and Oncology Center -

Yerevan, Armenia

Actively Recruiting

3

CHU Saint-Pierre Clinical Trials Unit

Brussels, Belgium

Completed

4

Universitair Ziekenhuis Brussel (UZBrussel) - Department of Anesthesiology and Perioperative Medicine

Brussels, Belgium

Completed

5

University Hospitals Leuven Pediatrisch hemato-oncology

Leuven, Belgium

Completed

6

University Clinical Hospital , Mostar

Mostar, Bosnia and Herzegovina

Actively Recruiting

7

Chu de Caen

Caen, France, 14033

Completed

8

Hôpital Béclère Service de Pédiatrie Centre de Référence des Maladies Héréditaires du Métabolisme Hépatique (CRMHMH)

Clamart, France

Completed

9

Hôpital Jeanne de Flandre Antenne du CIC pédiatrique - Niveau 0 CHU de Lille

Lille, France

Completed

10

Hôpital Armand Trousseau Service Hématologie et Oncologie Pédiatrique

Paris, France

Completed

11

Instituto Nazionale dei Tumori

Milan, Italy

Completed

12

Citta della Salute e della Scienza di Torino

Torino, Italy

Completed

13

Maternal and Child Health Institute IRCCS Burlo Garofolo, Pain and pediatric palliative care service

Trieste, Italy

Completed

14

National Center for Child Health and Development

Tokyo, Japan

Not Yet Recruiting

15

PHI University Clinic for Children's , Surgery

Skopje, North Macedonia

Actively Recruiting

16

University Clinic for Childrens Diseases , Department of Oncology, Hematology and , Malignant Hemopathy

Skopje, North Macedonia

Actively Recruiting

Loading map...

Research Team

S

Shionogi Clinical Trials Administrator Clinical Support Help Line

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here